Filing Analysis
iSpecimen Inc. entered into a three-month consulting agreement with IR Agency LLC for marketing and media distribution services. The company has committed to an aggregate cash fee of $2,000,000 to be paid by August 13, 2026.
🚩 Red Flags
- Extremely high cost for short-term marketing services ($2M for ~3 months/10 releases).
- Aggressive payment terms: Full $2,000,000 fee is non-refundable and due by the day after the agreement was signed (August 13, 2026).
- Lack of refundability even if the company terminates or the consultant ceases performance due to 'reputational risk'.
- Potential for high burn rate relative to micro-cap scale.
📋 Key Facts
- Agreement date: August 12, 2026
- Consultant: IR Agency LLC
- Services: Marketing, advertising, company profiles, and media distribution (max 10 news releases)
- Term: Three months commencing August 12, 2026
- Total Fee: $2,000,000 aggregate cash fee
- Payment Deadline: August 13, 2026
- Refund Policy: Non-refundable; no refund if Company terminates without cause or Consultant suspends due to perceived risk.
iSpecimen Inc. entered into a settlement agreement with WestPark Capital, Inc. to resolve an arbitration dispute regarding investment banking services related to a July 2025 public offering. The company paid $97,500 to settle all claims and terminate existing engagement agreements.
🚩 Red Flags
- Legal dispute with a previous underwriter/investment bank regarding a recent public offering (closed July 25, 2025).
📋 Key Facts
- Settlement Agreement signed on August 6, 2026.
- The dispute arose from arbitration (JAMS Ref. No. 5425005724) regarding engagement agreements dated July 31, 2025, and October 15, 2025.
- WestPark Capital had originally sought $269,999.91 in damages plus interest and fees.
- iSpecimen paid a settlement amount of $97,500 to resolve all claims.
- The Settlement Agreement terminates the Engagement Agreements in their entirety, including tail fees and rights of first refusal.
- The company expects to record the $97,500 charge in the quarter ending September 30, 2026.
iSpecimen Inc. closed a $5 million public offering consisting of common stock and pre-funded warrants to repay liabilities and fund working capital. The offering was conducted on a 'reasonable best efforts' basis via E.F. Hutton & Co.
🚩 Red Flags
- Significant dilution risk due to the issuance of pre-funded warrants for nearly 3x the number of common shares being sold in this round.
- Use of proceeds specifically mentions 'repayment of outstanding liabilities,' indicating potential liquidity pressure.
- 'Reasonable best efforts' basis suggests there is no guarantee all $5M would be raised.
📋 Key Facts
- Aggregate purchase price: $5,000,000 (potentially up to $5,000,285).
- Securities issued: 996,231 shares of Common Stock and pre-funded warrants to purchase up to 2,849,923 shares.
- Placement Agent: E.F. Hutton & Co.
- Fees: 4.0% cash fee on gross proceeds plus a 1% non-accountable expense allowance.
- Use of proceeds: Repayment of outstanding liabilities, potential acquisitions, investments in products/tech, marketing, and working capital.
- Offering closed on August 7, 2026.
iSpecimen Inc. has successfully completed Milestone 3 of its digital transformation program in partnership with SalesStack Solutions Corp. This milestone involves a $700,000 payment and focuses on expanding marketplace features, geographic reach, and ecosystem integrations.
📋 Key Facts
- Completed Milestone 3 of the digital transformation program powered by SalesStack Solutions Corp.
- Payment of $700,000 made upon completion of the milestone.
- Milestone 3 includes additional marketplace features, broader geographic rollout, and deeper partner ecosystem integrations.
- This follows previously completed Milestone 1 (Aug 21, 2025) and Milestone 2 (Feb 6, 2026).
iSpecimen Inc. received a notice from Nasdaq on May 29, 2026, stating the company is no longer compliant with Listing Rule 5550(b)(1) due to insufficient stockholders' equity.
🚩 Red Flags
- Severe equity deficiency: current equity ($814,038) is less than 33% of the required minimum ($2,500,000).
- Failure to meet any of the alternative Nasdaq listing standards.
- Risk of delisting if the compliance plan is rejected or if the company cannot raise significant capital quickly.
📋 Key Facts
- Nasdaq requires a minimum of $2,500,000 in stockholders' equity for continued listing on the Capital Market.
- As of the March 31, 2026 10-Q, the company's stockholders' equity was only $814,038.
- The company fails all alternative continued listing standards (equity, market value of listed securities, and net income).
- The company has 45 calendar days from May 29, 2026, to submit a compliance plan.
- If a plan is accepted, an extension of up to 180 days may be granted to regain compliance.
iSpecimen Inc. reported the results of its reconvened 2025 Annual Meeting of Stockholders held on May 29, 2026. The company successfully elected a Class I director, ratified its accounting firm, and approved a new 2025 Stock Incentive Plan.
🚩 Red Flags
- Extremely low voter turnout: Only 35.14% of eligible shares were represented, suggesting potential shareholder apathy or fragmentation in a micro-cap environment.
📋 Key Facts
- The Annual Meeting was held on May 29, 2026.
- Quorum was established with 2,979,059 shares present or represented by proxy (approximately 35.14% of the 8,478,579 eligible shares).
- Arphing (Tommy) Lee was elected as a Class I director for a term expiring at the 2028 Annual Meeting.
- Bush & Associates CPA LLC was ratified as the independent registered public accounting firm for the year ending December 31, 2025.
- The iSpecimen Inc. 2025 Stock Incentive Plan was approved by a majority of votes cast.
iSpecimen Inc. raised approximately $2.5 million through a private placement of common stock and pre-funded warrants while regaining Nasdaq bid price compliance. However, the company reported that its 2025 Annual Meeting has been adjourned for the sixth time due to a persistent lack of quorum.
🚩 Red Flags
- Extreme difficulty in obtaining a shareholder quorum, with six consecutive adjournments since December 2025.
- Reliance on a relatively small $2.5 million raise for basic working capital and marketing.
- Issuance of pre-funded warrants to allow investors to avoid the 4.99% beneficial ownership cap.
📋 Key Facts
- Entered into a Securities Purchase Agreement for 488,281 shares/warrants at $5.12 each.
- Gross proceeds of approximately $2.5 million before fees.
- Regained compliance with Nasdaq Minimum Bid Price Requirement (Rule 5550(a)(2)) as of May 12, 2026.
- The 2025 Annual Meeting has been adjourned six times (Dec 31, Jan 23, Feb 13, Mar 13, Apr 10, and May 8) due to lack of quorum.
- Intends to use up to $900,000 of the net proceeds specifically for marketing expenses.
iSpecimen Inc. implemented a 1-for-40 reverse stock split effective April 27, 2026, to regain compliance with Nasdaq's minimum bid price requirement. Additionally, the company ratified a 'defective corporate act' by filing a Certificate of Validation for a previous 1-for-20 reverse split from 2024 that was never properly filed with the State of Delaware.
🚩 Red Flags
- Large 1-for-40 reverse split ratio suggests significant share price erosion.
- History of non-compliance with Nasdaq minimum bid price requirements.
- Admission of a 'defective corporate act' regarding a previous 1-for-20 reverse split that was not legally finalized in 2024.
- Successive reverse splits (1:20 in 2024 and 1:40 in 2026) indicate chronic value destruction for long-term shareholders.
📋 Key Facts
- Effected a 1-for-40 reverse stock split on April 27, 2026.
- Common stock shares outstanding decreased from 52,639,796 to approximately 1,316,032.
- The split was intended to regain compliance with Nasdaq's minimum bid price requirement.
- Ratified a prior 1-for-20 reverse stock split from September 13, 2024, which was previously unfiled and deemed a 'defective corporate act'.
- Filed a Fifth Amended and Restated Certificate of Incorporation and a Certificate of Validation on April 29, 2026.
iSpecimen Inc. has failed to achieve a quorum for its 2025 Annual Meeting of Stockholders for the fifth consecutive time. The meeting, originally scheduled for December 31, 2025, has been adjourned multiple times and is now rescheduled for May 8, 2026.
🚩 Red Flags
- Persistent failure to achieve a quorum (5 consecutive failed attempts).
- Significant delay in corporate governance, with the annual meeting now delayed by over four months.
- Potential shareholder apathy or difficulty in reaching the required voting threshold for micro-cap governance.
📋 Key Facts
- The 2025 Annual Meeting was originally convened on December 31, 2025.
- Quorum was not present at the original meeting or the reconvened meetings on January 23, February 13, March 13, and April 10, 2026.
- The meeting has been adjourned to May 8, 2026, at 9:00 a.m. Eastern Time.
- The record date for stockholders entitled to vote remains November 3, 2025.
- The proposals to be voted on remain unchanged from the definitive proxy statement filed on November 21, 2025.
iSpecimen Inc. announced a significant operational milestone, achieving an 85% reduction in shipping times for human biospecimens. This update was disclosed via a press release on April 9, 2026, and filed under Regulation FD.
📋 Key Facts
- The company issued a press release titled 'iSpecimen Achieves 85% Reduction in Human Biospecimen Shipping Time' on April 9, 2026.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- The report was signed by CEO Katharyn Field on April 10, 2026.
iSpecimen Inc. has adjourned its 2025 Annual Meeting of Stockholders for the fourth consecutive time due to a lack of quorum. The meeting, originally scheduled for December 31, 2025, has been pushed to April 10, 2026.
🚩 Red Flags
- Repeated failure (4 times) to achieve a quorum for a mandatory annual meeting.
- Potential risk of non-compliance with Nasdaq Listing Rule 5620(a), which requires companies to hold an annual meeting of shareholders within one year of the end of the fiscal year.
- High level of shareholder apathy or difficulty in soliciting votes, which may hinder the company's ability to pass critical corporate actions.
📋 Key Facts
- The 2025 Annual Meeting was originally convened on December 31, 2025.
- The meeting has been adjourned and reconvened on January 23, 2026, February 13, 2026, and March 13, 2026, failing to reach a quorum each time.
- The next reconvened meeting is scheduled for April 10, 2026, at 9:00 a.m. Eastern Time.
- The record date for stockholders remains November 3, 2025.
- No changes have been made to the proposals described in the Proxy Statement filed November 21, 2025.
iSpecimen Inc. announced the immediate resignation of independent director Siyun Yang on February 17, 2026. Ms. Yang's departure was not due to any disagreements with the company's operations, policies, or practices.
🚩 Red Flags
- The resignation creates a vacancy on the Audit Committee, which may require a timely replacement to maintain Nasdaq compliance.
- Relatively short tenure of approximately one year for the departing director.
📋 Key Facts
- Ms. Siyun Yang resigned as a director effective February 17, 2026.
- Ms. Yang had served as an independent director since February 2025.
- She was a member of the Audit Committee and the Nominating and Corporate Governance Committee.
- The company stated there were no disagreements regarding operations, policies, or practices.
iSpecimen Inc. reported that it has failed to achieve a quorum at its 2025 Annual Meeting of Stockholders across multiple reconvened sessions. The company has adjourned the meeting again and intends to reconvene on March 13, 2026.
🚩 Red Flags
- Repeated failure to achieve quorum suggests significant shareholder apathy or lack of engagement.
- Inability to conduct official business (voting on proposals) can delay critical corporate actions such as director elections or auditor appointments.
📋 Key Facts
- The 2025 Annual Meeting was originally scheduled for December 31, 2025.
- Quorum was not present at the original meeting or subsequent reconvened meetings on January 23, 2026, and February 13, 2026.
- The next meeting is scheduled for March 13, 2026, at 9:00 a.m. ET.
- The record date remains November 3, 2025.
iSpecimen Inc. issued two press releases regarding operational milestones and site network performance. The company announced the completion of Milestone 2 in its digital transformation program and the activation of its live production marketplace.
📋 Key Facts
- Completed 'Milestone 2' of a digital transformation program powered by SalesStack Solutions on February 6, 2026.
- Activated the Company’s live production marketplace.
- Reported operational achievements regarding site network responsiveness, specifically in rapid influenza specimen procurement.
iSpecimen Inc. has failed to achieve a quorum at its 2025 Annual Meeting of Stockholders for the second consecutive time. The company has adjourned the meeting and plans to reconvene on February 13, 2026.
🚩 Red Flags
- Repeated failure to achieve a quorum at annual meetings suggests significant shareholder apathy or lack of engagement.
- Inability to pass routine stockholder proposals can lead to governance issues and delays in required corporate actions.
📋 Key Facts
- The 2025 Annual Meeting was originally scheduled for December 31, 2025, but was adjourned due to lack of quorum.
- The meeting reconvened on January 23, 2026, but failed to achieve a quorum again.
- The Company intends to reconvene the meeting on February 13, 2026.
- The record date for the Annual Meeting remains November 3, 2025.
iSpecimen Inc. filed an amendment to its Series C Convertible Non-Voting Preferred Stock Certificate of Designation to include anti-dilution adjustments for conversion and floor prices in the event of a reverse stock split or share combination.
🚩 Red Flags
- Explicit provision for anti-dilution adjustments in the event of a reverse stock split, which often indicates an imminent or recent need to boost share price to maintain exchange compliance.
- The filing is an amendment (8-K/A) to a previous filing, indicating ongoing structural changes to capital structure.
📋 Key Facts
- Filed Amendment No. 1 to Form 8-K on January 16, 2026.
- Amends Section 7 of the Series C Preferred Stock Certificate of Designation.
- The amendment ensures Conversion Price and Floor Price are subject to proportionate adjustment upon any reverse stock split or share combination.
- Amendment was approved by the Company and holders of more than a majority of Series C Preferred Stock.
iSpecimen Inc. adjourned its 2025 Annual Meeting of Stockholders on December 31, 2025, because a quorum was not achieved. The company plans to reconvene the meeting on January 23, 2026.
🚩 Red Flags
- Failure to achieve a quorum at the annual meeting suggests low shareholder engagement or potential proxy solicitation challenges.
📋 Key Facts
- Annual Meeting held on December 31, 2025, failed to reach a quorum.
- Meeting adjourned to allow more time for stockholder voting.
- Reconvene date set for January 23, 2026.
- Record date remains November 3, 2025.
iSpecimen Inc. entered into a $2,000,000 consulting agreement with IR Agency LLC for marketing and investor communications services. The fee was paid upfront using proceeds from a recent Series C Convertible Non-Voting Preferred Stock private placement.
🚩 Red Flags
- High cash outflow ($2M) relative to typical micro-cap marketing spends, paid entirely upfront.
- Potential conflict of interest/related party risk: The fee is being funded directly by the proceeds of a recent equity raise, which could be viewed as using investor capital for aggressive IR/marketing rather than operations.
- The consultant's role in 'investor communications' combined with an immediate $2M cash payout can sometimes signal attempts to artificially bolster stock sentiment.
📋 Key Facts
- Consulting Agreement signed on December 31, 2025, with IR Agency LLC.
- Aggregate cash fee of $2,000,000 payable upon execution.
- Services include marketing, advertising, and digital community-building.
- Initial term is four (4) months commencing December 31, 2025.
- Funding for the fee was sourced from a Series C Convertible Non-Voting Preferred Stock private placement completed on Dec 31, 2025.
iSpecimen Inc. entered into a $5.5 million securities purchase agreement to issue Series C Convertible Non-Voting Preferred Stock to accredited investors. The offering includes a floating conversion price at a 15% discount to the market price, subject to a floor price of $0.0681.
🚩 Red Flags
- Death Spiral Feature: The 15% discount on floating conversion price can lead to significant dilution if the stock price declines.
- Deep Discount: Investors are purchasing shares at $800 despite a stated value of $1,000 per share.
- Low Floor Price: A floor price of $0.0681 suggests the company is seeking capital under highly distressed valuation terms.
📋 Key Facts
- Aggregate sale amount: $5.5 million via 6,875 shares of Series C Preferred Stock.
- Issue price: $800 per share (stated value is $1,000 per share).
- Conversion terms: Convertible into common stock at 85% of the closing price on the day preceding conversion.
- Floor Price: Conversion price cannot be less than $0.0681 per share.
- Series C Preferred Stock is non-voting but carries protective provisions regarding charter amendments and rights changes.
- The offering includes a Registration Rights Agreement for the resale of conversion shares.
iSpecimen Inc. has regained compliance with Nasdaq continued listing requirements regarding stockholders' equity, market value of listed securities, and net income. The Nasdaq Listing Qualifications Staff has notified the company that the deficiency matter is now closed.
🚩 Red Flags
- Historical non-compliance with minimum stockholders' equity and market value requirements (previously disclosed in June 2025).
📋 Key Facts
- Nasdaq Staff determined the Company complies with Rules 5550(b)(1), 5550(b)(2), and 5550(b)(3 as of November 28, 2025.
- Compliance was achieved based on stockholders' equity of $3,072,711 reported in the 10-Q for the period ended September 30, 2025.
- The deficiency notice originally dated June 4, 2025, is now officially resolved and closed.
iSpecimen Inc. received a notice from Nasdaq stating it is no longer in compliance with the minimum $1.00 bid price requirement after its stock closed below $1.00 for 30 consecutive business days. The company has been granted an initial 180-day period to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Minimum bid price deficiency (stock trading below $1.00)
- Potential for a mandatory reverse stock split to regain compliance
📋 Key Facts
- Nasdaq issued a notice on November 19, 2025, regarding non-compliance with Nasdaq Listing Rule 5550(a)(2).
- The deficiency is due to the closing bid price being below $1.00 for 30 consecutive business days.
- The company has an initial compliance period until May 18, 2026.
- To regain compliance, the stock must close at or above $1.00 for a minimum of 10 (or up to 20) consecutive business days.
- Failure to regain compliance may lead to delisting, though an additional 180-day extension may be available if certain criteria are met.
iSpecimen Inc. announced a major leadership transition on November 7, 2025, involving the appointment of Katharyn Field as CEO and the resignation of Robert Bradley Lim from all executive and board positions. The company also appointed Arphing (Tommy) Lee to the Board and various committees to fill vacancies.
🚩 Red Flags
- Sudden departure of the CEO, Secretary, and Treasurer (simultaneous exit from all key roles).
- Rapid leadership turnover: Mr. Lim had only served in his capacity since December 2024.
📋 Key Facts
- Katharyn Field appointed as Chief Executive Officer, Secretary, and Treasurer, effective November 7, 2025.
- Ms. Field previously served as President since February 2025 and a Director since September 2024.
- Robert Bradley Lim resigned as CEO, Secretary, Treasurer, and from the Board of Directors, effective immediately.
- The company stated Mr. Lim's resignation did not involve any disagreements with management or the Board.
- Arphing (Tommy) Lee appointed as an independent director to fill a board vacancy; also joined Audit and Nominating/Governance committees.
- Management claims no anticipated disruption to operations due to these changes.
iSpecimen Inc. held a special meeting of stockholders where all six proposals were approved, most notably a reverse stock split and an increase in authorized shares to facilitate future financing.
🚩 Red Flags
- Approval of a reverse stock split (often used to maintain Nasdaq listing requirements or combat low share prices).
- Massive increase in authorized shares (from 250M to 1B), indicating significant potential future dilution.
- Approval for equity line of credit and private financing under Nasdaq Rule 5635(d) suggests a need for immediate capital through highly dilutive means.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio ranging from 1:10 to 1:100, to be determined by the Board.
- Authorized shares increased significantly from 250,000,000 to 1,000,000,000.
- Shareholders approved exemptions under Nasdaq Listing Rule 5635(d) for private financing transactions and an equity line of credit (ELOC), allowing issuances exceeding 19.99% of outstanding shares at prices potentially below the Minimum Price.
- Approved an amendment to increase the conversion price floor for certain convertible securities from 50% to 80% of the VWAP.
- Quorum was met with approximately 36% of shares (1,437,502 shares) represented at the meeting.
iSpecimen Inc. provided an update on its strategic initiative to integrate digital assets into its business model, specifically targeting a Solana-based corporate treasury reserve of up to $200 million. The company is exploring opportunities in tokenized real-world assets and high-ranking cryptocurrencies.
🚩 Red Flags
- Significant shift in business focus/strategy toward high-volatility digital assets (Solana ecosystem).
- Potential for significant balance sheet volatility due to the proposed $200 million treasury reserve target.
- Speculative nature of 'tokenized real-world assets' integration.
📋 Key Facts
- Company aims to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem.
- The initiative was originally announced in August 2025.
- Management is currently evaluating opportunities in tokenized real-world assets and highly ranked cryptocurrencies.
- The company has been approached by several cryptocurrency-related companies regarding these initiatives.
iSpecimen Inc. announced the successful completion of Milestone 1 in its digital transformation program via Salestack Solutions. This milestone involved installing a new platform and provisioning modern infrastructure to improve operational efficiency.
📋 Key Facts
- Completed Milestone 1 of digital transformation program powered by Salestack Solutions on August 21, 2025.
- Milestone 1 included the installation of the Salestack platform and provisioning of modern infrastructure.
- The company is moving toward Milestone 2 (Integration) to connect business operations, customer engagement, and data management.
iSpecimen Inc. announced a major strategic initiative to integrate digital assets into its business model, specifically aiming to build a corporate treasury reserve of up to $200 million within the Solana blockchain ecosystem.
🚩 Red Flags
- Significant pivot in business model/treasury strategy (digital assets) which introduces high volatility and regulatory risk.
- The scale of the proposed reserve ($200M) is highly ambitious relative to typical micro-cap profiles, raising questions about funding sources.
📋 Key Facts
- Strategic initiative to integrate digital assets into the company's business model.
- Targeting a corporate treasury reserve of up to $200 million.
- The proposed reserve is to be built around the Solana blockchain ecosystem.
- Announcement made via press release on August 7, 2025.
iSpecimen Inc. completed a private placement of 1,559,828 shares (or pre-funded warrants) at $1.12 per share, raising approximately $1.75 million in gross proceeds. The offering was conducted under Nasdaq Rule 5635(d), allowing for an issuance exceeding 20% of outstanding stock without shareholder approval.
🚩 Red Flags
- Significant dilution: The issuance was conducted under Nasdaq Rule 5635(d), indicating the offering represents 20% or more of the company's outstanding common stock.
- High burn/expense allocation: A disproportionate amount of the net proceeds ($500,000 out of ~$1.75M gross) is being directed toward a single-month marketing contract with IR Agency LLC.
- Registration Rights Agreement: The company is required to file a registration statement within 15 days of closing to allow investors to resell their shares, which typically leads to immediate downward pressure on the stock price.
📋 Key Facts
- Private placement closed on August 4, 2025.
- Total shares/warrants issued: 1,559,828.
- Price per share/warrant: $1.12 (or $1.1219 for pre-funded warrants).
- Gross proceeds: approximately $1.75 million.
- WestPark Capital, Inc. acted as exclusive placement agent with a 4.0% cash commission.
- $500,000 of net proceeds is earmarked specifically for marketing and advertising services via IR Agency LLC.
iSpecimen Inc. completed a public offering of common stock and pre-funded warrants on July 25, 2025, raising approximately $4 million in gross proceeds at a price of $0.70 per security.
🚩 Red Flags
- Significant dilution: The offering includes over 4.2 million pre-funded warrants which are immediately exercisable (subject to ownership caps).
- Low share price: Pricing at $0.70 is characteristic of micro-cap companies facing liquidity constraints.
- High burn/expense allocation: A significant portion ($1.5M) of the net proceeds is earmarked for marketing and advertising services via a consulting agreement.
📋 Key Facts
- Offered 1,482,644 shares of common stock and 4,231,639 pre-funded warrants.
- Offering price: $0.70 per share / $0.6999 per Pre-Funded Warrant.
- Gross proceeds: ~$4,000,000; Net proceeds: ~$3,528,902.
- Underwriter: WestPark Capital, Inc.
- $1,500,000 of net proceeds allocated to IR Agency LLC for marketing/advertising services.
- $1,000,000 of net proceeds allocated to Sales Stack Solutions Corp. for a software purchase milestone.
iSpecimen Inc. amended its Second Amended and Restated Bylaws to reduce the quorum requirement for shareholder meetings from a majority of voting power to 34% of voting power.
🚩 Red Flags
- Reduction in quorum requirements can make it easier for a minority of shareholders to conduct official business or approve corporate actions, potentially reducing protections for minority holders.
📋 Key Facts
- Amendment effective date: July 9, 2025
- Quorum requirement reduced from >50% (majority) to 34% of outstanding shares entitled to vote.
- The amendment modifies the Company's Second Amended and Restated Bylaws.
iSpecimen Inc. announced the immediate resignation of two Board members, including Chairman Richard J. Paolone and John L. Brooks III, effective June 18, 2025. To fill the vacancies, the company appointed Anthony Lau to the Board and several committees.
🚩 Red Flags
- Simultaneous departure of the Board Chairman (Paolone) and a long-standing director/Audit Committee Chair (Brooks).
📋 Key Facts
- Richard J. Paolone resigned as Director and Chairman of the Board on June 18, 2025.
- John L. Brooks III resigned from the Board on June 18, 2025; he previously served as Chair of the Audit Committee.
- Anthony Lau was appointed to the Board on June 20, 2025, filling a vacancy and joining the Audit, Compensation, and Nominating/Governance committees.
- The company stated that neither resignation involved disagreements with management or operations per Item 5.02(a).
- Anthony Lau brings experience as CEO, CFO, and Director of Remington Resources, Inc.
iSpecimen Inc. received a notice from Nasdaq stating it is non-compliant with the minimum stockholders' equity requirement of $2.5 million. As of March 31, 2025, the company reported only $1,668,513 in stockholders' equity.
🚩 Red Flags
- Delisting notice for failure to meet minimum stockholders' equity requirements.
- Significant capital deficiency (approx. $831,487 below the required threshold).
- Failure to meet alternative listing criteria (market value or net income) reduces recovery options.
📋 Key Facts
- Received Nasdaq notice on June 4, 2025, regarding non-compliance with Nasdaq Listing Rule 5550(b)(1).
- Stockholders' equity was $1,668,513 as of March 31, 2025 (per Form 10-Q).
- Company does not meet alternative listing criteria regarding market value or net income.
- The company has 45 calendar days from the notice date to submit a compliance plan.
- If a plan is accepted, an extension of up to 180 days may be granted to evidence compliance.
iSpecimen Inc. announced the immediate resignation of its independent auditor, Wolf & Company, P.C., and the subsequent appointment of Bush & Associates CPA LLC as its new auditor for the fiscal year ending December 31, 2024.
🚩 Red Flags
- Immediate resignation of the previous auditor (Wolf & Company).
- Existence of a 'going concern' explanatory paragraph in the 2023 audit report.
- Auditor change combined with existing going concern uncertainty (Red Flag Escalator).
📋 Key Facts
- Wolf & Company, P.C. resigned as the independent registered public accounting firm effective March 7, 2025.
- The audit report for the fiscal year ended December 31, 2023, included an explanatory paragraph regarding a going concern uncertainty.
- Bush & Associates CPA LLC was appointed on March 10, 2025, to serve as the new auditor for the fiscal year ending December 31, 2024.
- The company stated there were no disagreements with the outgoing auditor regarding accounting matters or auditing procedures.
This is an amendment (8-K/A) to a previous filing, specifically disclosing the finalized compensation terms for Katharyn Field, who was appointed as President of the Company on February 19, 2025.
📋 Key Facts
- Katharyn Field appointed as President on February 19, 2025.
- Annual base salary set at $240,000.
- Eligible for the Company’s Stock Incentive Plan and standard fringe benefits.
- Employment is 'at-will' with a 30-day notice period required by either party.
iSpecimen Inc. announced a significant leadership restructuring effective February 19, 2025, including the appointment of Katharyn Field as President and several changes to the Board of Directors and committee compositions.
🚩 Red Flags
- Significant leadership turnover involving the President and Board Chair roles simultaneously.
- Compensation for the new President has not yet been determined, necessitating a future amendment to this filing.
📋 Key Facts
- Katharyn Field appointed as President, effective immediately (Feb 19, 2025).
- Ms. Field resigned from the Board of Directors.
- Siyun Yang appointed as an independent director to fill Ms. Field's Board vacancy.
- Siyun Yang appointed to the Audit Committee and Nominating and Corporate Governance Committee.
- Richard Paolone appointed as Chair of the Board, replacing Ms. Field.
- Robert Bradley Lim remains CEO and a member of the Board.
iSpecimen Inc. announced it has secured suppliers for human metapneumovirus (hMPV) specimens to address potential demand for disease study and vaccine development.
📋 Key Facts
- Company secured suppliers for flu-like human metapneumovirus (hMPV).
- The move is intended to position the company for specimen demand related to hMPV research and vaccine development.
- The announcement was made on January 16, 2025.
iSpecimen Inc. announced that CEO Robert Bradley Lim has been appointed to the additional roles of Treasurer and Secretary of the Company, effective December 27, 2024.
📋 Key Facts
- Effective Date: December 27, 2024
- Appointee: Robert Bradley Lim
- New Roles: Treasurer and Secretary (in addition to CEO)
- Compensation: No changes were made to Mr. Lim's compensation or employment terms.
iSpecimen Inc. appointed Yuying Liang, CPA, as Chief Financial Officer effective December 13, 2024. The appointment is structured through an engagement with Yuying Liang Professional Corp. rather than a direct employee hire.
🚩 Red Flags
- CFO is being hired through an external professional corporation rather than as a direct employee, which can sometimes indicate cost-cutting or a desire for flexible/fractional leadership in micro-cap companies.
- The use of a fractional CFO model often suggests the company may be managing cash flow tightly.
📋 Key Facts
- Effective Date: December 13, 2024
- New CFO: Yuying Liang, CPA (via Yuying Liang Professional Corp.)
- Compensation Structure: Monthly fee of $25,000 USD plus taxes and expenses
- Contract Terms: 60-day written notice for termination by either party
- Strategic Focus: Company announced a strategic shift toward high-demand cancer biospecimens for 2025.
iSpecimen Inc. announced the positive results of its Next Day Quote (NDQ) program, a service designed to accelerate biospecimen transaction pricing for researchers.
📋 Key Facts
- The company launched/announced results for the 'Next Day Quote' (NDQ) program on December 13, 2024.
- The NDQ program aims to provide accurate biospecimen sample pricing within 24 hours of a customer request.
- The announcement is intended to accelerate the biospecimen transaction process for researchers and providers.
iSpecimen Inc. announced the appointment of Robert Bradley Lim as Chief Executive Officer and a member of the Board of Directors, effective December 9, 2024.
🚩 Red Flags
- CEO is being hired through a personal corporation (1513932 B.C. Ltd.) rather than as a direct employee, which can sometimes complicate standard employment structures in micro-caps.
📋 Key Facts
- Robert Bradley Lim appointed as CEO and Board Member on December 9, 2024.
- Lim will be paid through his personal corporation, 1513932 B.C. Ltd., at an annual fee of $270,000.
- The compensation is payable in equal monthly installments.
- Lim has no familial relationships with existing directors or officers and no disclosed legal proceedings under Item 401(f).
- The appointment was formalized via an Independent Contractor Agreement.
iSpecimen Inc. announced the departure of its CEO, CFO, and Treasurer, Tracy Curley, effective November 8, 2024. The separation is characterized by a dispute between the company and Ms. Curley regarding whether her exit was a resignation or a termination.
🚩 Red Flags
- Sudden departure of both CEO and CFO simultaneously.
- Explicit mention of 'differences' between management and the Board regarding company direction.
- Dispute over the nature of the separation (resignation vs. termination) suggests potential litigation or governance friction.
📋 Key Facts
- Tracy Curley has ended her employment as CEO, CFO, and Treasurer of iSpecimen Inc.
- Ms. Curley resigned from the Board of Directors on November 8, 2024.
- The separation was due to 'differences between Ms. Curley and the Board regarding the future direction of the Company.'
- There is an active dispute over whether the departure constitutes a resignation or a termination.
iSpecimen Inc. completed a 'reasonable best efforts' public offering of common stock and pre-funded warrants to raise approximately $5 million. Additionally, the company entered into a highly unusual $2 million investor relations agreement for marketing services.
🚩 Red Flags
- Extremely high cost of investor relations: The $2M IR fee represents roughly 40% of the total gross proceeds from the offering.
- Short-term/unusual contract structure: A $2 million payment for a one-month term is highly irregular for a micro-cap company.
- Dilutive offering: Issuance of significant pre-funded warrants (up to 1.5M shares) will cause substantial dilution to existing shareholders.
📋 Key Facts
- Offered 132,814 shares of common stock and up to 1,533,852 pre-funded warrants at $3.00 per share.
- Aggregate gross proceeds estimated at $4,998,464 (up to $4,999,998 with full warrant exercise).
- Placement Agent (WestPark Capital, Inc.) received a 4.0% cash fee plus expenses.
- Entered into an Investor Relations Agreement with IR Agency LLC for $2,000,000 in cash for marketing/advertising services.
- The IR agreement has an initial term of only one month and is terminable by either party at any time.
- Proceeds are intended for debt repayment, acquisitions, R&D, and working capital.
iSpecimen Inc. announced the resignation of its Chief Information Officer, Benjamin Bielak, and a subsequent demand for arbitration by Mr. Bielak regarding unpaid bonuses and severance. Additionally, the company reported it has regained compliance with Nasdaq's minimum bid price requirement.
🚩 Red Flags
- Legal dispute/Arbitration involving a former C-suite executive.
- Significant potential liability of $586,800 plus legal fees regarding compensation disputes.
- History of Nasdaq delisting deficiency notices (though currently resolved).
📋 Key Facts
- Benjamin Bielak resigned as Chief Information Officer effective July 14, 2024.
- Mr. Bielak filed a Demand for Arbitration with the American Arbitration Association claiming unpaid bonuses for 2023 and 2024 and severance payments.
- The total claim amount sought by Mr. Bielak is $586,800 plus attorneys' fees and interest.
- iSpecimen Inc. intends to vigorously defend against the claims, stating they lack legal or factual basis.
- Nasdaq confirmed on October 1, 2024, that the company regained compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) after stock closed at $1.00 or greater between Sept 16 and Sept 30, 2024.
iSpecimen Inc. entered into a $1,000,000 note purchase agreement with an undisclosed lender, resulting in the immediate resignation of three board directors and their replacement by three individuals designated by the lender. This transaction includes high-interest debt (18% per annum) and a contingent revolving credit facility tied to a future $5 million public offering.
🚩 Red Flags
- High-interest debt (18% per annum) indicates potential liquidity pressure or high risk profile.
- Board takeover: The lender successfully replaced 60% of the board (3 out of 5 directors).
- Debt maturity is short-term (within 12 months), creating significant refinancing risk.
- Contingent credit facility is tied to a large $5M public offering, suggesting the company may struggle to raise capital through traditional means.
📋 Key Facts
- Company entered into a Note Purchase Agreement on September 19, 2024.
- Lender provided net funds of $960,000 in exchange for a $1,000,000 promissory note.
- The note carries an interest rate of 18% per annum and is payable within 12 months.
- A contingent revolving line of credit of up to $1,000,000 is available if the company files a registration statement for a public offering of at least $5,000,000.
- Three directors (Steven Gullans, Theresa Mock, and Elizabeth A. Graham) resigned effective September 25, 2024.
- The Lender appointed three new directors: Richard Paolone, Avtar Dhaliwal, and Katherine Field.
- Westpark Capital, Inc. acted as placement agent for a $40,000 fee.
iSpecimen Inc. is implementing a 1-for-20 reverse stock split to increase its share price, effective September 13, 2024. The move follows stockholder approval from the July 19, 2024 annual meeting.
🚩 Red Flags
- Reverse stock split is a high-impact event often used by micro-cap companies to avoid delisting from major exchanges due to low share prices.
- The implementation of a reverse split can sometimes lead to increased volatility and downward pressure on the adjusted share price.
📋 Key Facts
- Reverse stock split ratio: 1-for-20 (1:20).
- Effective date of the reverse split: September 13, 2024, at 4:30 p.m. ET.
- Trading on a split-adjusted basis begins: September 16, 2024.
- The company will continue to trade on Nasdaq under the symbol 'ISPC'.
- New CUSIP number for common stock: 45032V207.
iSpecimen Inc. filed an 8-K to announce its second quarter 2024 financial and operating results, accompanied by a press release and an investor presentation.
🚩 Red Flags
- The company explicitly mentions risks including 'lack of profitability' and 'continued capital needs' in its forward-looking statement disclosures.
📋 Key Facts
- Report date: August 6, 2024
- Reporting period: Quarter ended June 30, 2024
- The company issued an Earnings Release (Exhibit 99.1) and an Investor Presentation (Exhibit 99.2).
- Financial statements for the quarter were filed via Form 10-Q on August 6, 2024.
iSpecimen Inc. announced the results of its annual meeting where stockholders approved a proposal for a reverse stock split with a ratio between 1-for-10 and 1-for-20. Additionally, the company reported the resignation of director Andrew L. Ross.
🚩 Red Flags
- Approval of a reverse stock split (often used to maintain Nasdaq listing compliance or improve share price).
- Director departure (though noted as non-dispute related).
📋 Key Facts
- Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split.
- The reverse split ratio will be set by the Board within a range of 1-for-10 to 1-for-20.
- Director Andrew L. Ross resigned effective July 25, 2024; no disagreements were reported.
- Two Class III directors (Tracy Curley and Elizabeth A. Graham) were elected to three-year terms.
- Wolf & Company, P.C. was ratified as the independent registered public accounting firm for FY2024.
iSpecimen Inc. announced the resignation of Benjamin Bielak from his roles as Chief Information Officer and Secretary, effective July 15, 2024.
📋 Key Facts
- Benjamin Bielak is resigning as Chief Information Officer (CIO) and Secretary.
- The resignation was received via written notice on July 5, 2024.
- The departure is effective July 15, 2024.
iSpecimen Inc. has entered into a new commercial lease for office space in Woburn, MA, and simultaneously issued a termination notice for its existing Lexington, MA lease effective August 31, 2024.
🚩 Red Flags
- Significant reduction in office footprint from ~8,835 sq. ft. to ~2,273 sq. ft., suggesting cost-cutting or downsizing of operations.
📋 Key Facts
- Entered into a new 5-year lease (Woburn Lease) with Cummings Properties, LLC on July 2, 2024.
- New premises: ~2,273 sq. ft. at 8 Cabot Road, Suite 1800, Woburn, MA.
- Base rent for new space: $72,736 per year ($6,061.33 per month), with a 5% annual cap on CPI adjustments.
- Security deposit paid: $12,122.00.
- Term of new lease commences September 1, 2024 and terminates August 30, 2029 (Note: Text says Aug 30, 2025 but context implies a 5-year term).
- Terminated Lexington Lease effective August 31, 2024.
- Paid $5,131.27 as an estimated termination payment for the Lexington lease.
iSpecimen Inc. announced the scheduling of its 2024 Annual Meeting of Stockholders and provided updated deadlines for stockholder proposals.
📋 Key Facts
- The 2024 Annual Meeting of Stockholders is scheduled for July 19, 2024.
- The record date for voting eligibility is the close of business on June 3, 2024.
- Revised deadline for stockholder proposals under Rule 14a-8 to be included in proxy materials is May 27, 2024.
- Deadline for director nominations or other non-Rule 14a-8 proposals is also set as May 27, 2024.
iSpecimen Inc. filed an 8-K to announce its financial and operating results for the first quarter ended March 31, 2024, concurrently with the filing of its Form 10-Q.
🚩 Red Flags
- Forward-looking statements acknowledge risks including 'lack of profitability' and 'continued capital needs'.
📋 Key Facts
- Reported earnings and operating results for the quarter ended March 31, 2024.
- Issued an investor presentation dated May 2024 as Exhibit 99.2.
- Conducted a conference call and audio webcast on May 7, 2024, to discuss quarterly results.
iSpecimen Inc. has failed to regain compliance with Nasdaq's $1 minimum bid price requirement by the initial deadline of April 8, 2024. However, Nasdaq has granted the company a second 180-day compliance period extending until October 7, 2024.
🚩 Red Flags
- Delisting notice/Non-compliance with minimum bid price requirement
- Continued failure to maintain stock price above $1.00 threshold
- Risk of imminent delisting if second compliance period is not met
📋 Key Facts
- The Company failed to meet the $1 minimum bid price requirement by the initial April 8, 2024 deadline.
- Nasdaq has granted a second compliance period of 180 days, expiring October 7, 2024.
- Compliance can be achieved if the stock closes at $1.00 or higher for 10 consecutive business days during the extension period.
- Failure to regain compliance by October 7, 2024, will result in delisting notification and potential appeal to a Hearings Panel.
iSpecimen Inc. has appointed Elizabeth A. Graham to the Board of Directors as a Class III director, filling the vacancy left by Joseph J. Basile's resignation.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Appointment date: March 21, 2024.
- Elizabeth A. Graham joins as a Class III director and member of the nominating and corporate governance committee.
- Ms. Graham replaces Joseph J. Basile, who resigned effective December 31, 2023.
- The Board has determined Ms. Graham is an 'independent director' per Nasdaq Listing Rule 5605(a)(2).
- Ms. Graham will receive standard nonemployee director compensation and enter into an indemnification agreement.
iSpecimen Inc. filed an 8-K to announce its fiscal year 2023 financial and operating results via a press release and investor presentation. The filing serves as a formal announcement of the company's annual earnings release.
🚩 Red Flags
- The company's forward-looking statements explicitly mention risks including 'lack of profitability', 'continued capital needs', and 'lack of a long operating history'.
📋 Key Facts
- Announced financial and operating results for the fiscal year ended December 31, 2023.
- The audited financial statements for FY2023 were filed in the Annual Report on Form 10-K on March 13, 2024.
- Held an earnings conference call and audio webcast on March 14, 2024.
- Provided an updated investor presentation dated March 2024.
iSpecimen Inc. entered into an At the Market (ATM) Offering Agreement with Rodman & Rensshaw LLC to facilitate the sale of up to $1,500,000 in common stock.
🚩 Red Flags
- Potential for immediate share dilution to existing shareholders.
📋 Key Facts
- Entered into ATM Agreement on March 5, 2024.
- Aggregate offering amount: up to $1,500,000.
- Sales Agent: Rodman & Renshaw LLC.
- Agent compensation is capped at 3.0% of gross sales price.
- Shares will be sold via Nasdaq or other existing trading markets under an existing S-3 registration statement (File No 333-265976).
iSpecimen Inc. entered into a repurchase and termination agreement to buy back warrants issued in December 2021. This action effectively cancels the potential issuance of up to 1,312,500 shares of common stock.
🚩 Red Flags
- The extremely low repurchase price ($0.04) relative to the original exercise price ($13.00) suggests the warrants were significantly out-of-the-money and likely held no intrinsic value for holders, necessitating a nominal payment to terminate the obligation.
📋 Key Facts
- Repurchase date: February 13, 2024
- Warrants were originally issued on December 1, 2021, with an exercise price of $13.00 per share.
- The repurchase price is set at $0.04 per share issuable under the warrants.
- Total maximum shares subject to repurchase: 1,312,500 shares.
- Termination includes all related Securities Purchase Agreements and Registration Rights Agreements dated November 28, 2021.